Showing results (571-580 of 586) with videos related to
Sort By:
Pageof 59
Cancer Cell|June 12, 2019
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining EfficacyYong Fang, Daniel J McGrail, Chaoyang Sun, et al.Cancer Discovery|June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted TherapyAlexander Drilon, Manish R Sharma, Melissa L Johnson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.The Oncologist|March 14, 2026
Telemedicine as a Gateway to Early-Phase Oncology Trials: Lessons from 14,000 Patients and Future Directions for Global Access and EquityCarlos Torrado, Clark R Andersen, Lei Kang, et al.Cancer Research|September 14, 2021
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerKurt W Evans, Erkan Yuca, Stephen S Scott, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional studyJoo Ern Ang, Charlie Gourley, C Bethan Powell, et al.Cancer Treatment Reviews|May 21, 2019
Improving attribution of adverse events in oncology clinical trialsGoldy C George, Pedro C Barata, Alicyn Campbell, et al.Cancer Discovery|September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Joline S J Lim, Iain R Macpherson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2022
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of ResponseTimothy A Yap, Justin F Gainor, Margaret K Callahan, et al.Journal of Medicinal Chemistry|December 4, 2024
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid CancersChristopher L Carroll, Michael G Johnson, Yanbing Ding, et al.Pageof 59